浙江康恩贝制药股份有限公司2025年第二次临时股东会决议公告

Group 1 - The company held its second extraordinary general meeting of shareholders on December 22, 2025, with no resolutions being rejected [2] - The meeting was convened by the board of directors and chaired by director Zhou Fan, following legal and procedural requirements [2][3] - Two new non-independent directors, Ying Xuejie and Jin Junli, were approved to join the company's eleventh board of directors [4][5] Group 2 - The second largest shareholder, Kang En Bei Group, currently holds 229,188,571 shares, representing 9.044% of the total share capital [9] - Kang En Bei Group plans to reduce its holdings by up to 50,659,020 shares, which is no more than 2% of the total share capital, through block trading [10] - The controlling shareholder, Zhejiang Pharmaceutical Health Industry Group, is set to be the buyer in this transaction [10] Group 3 - Zhejiang Pharmaceutical Health Industry Group intends to increase its stake by acquiring 50,659,020 shares, which is approximately 1.999% of the total share capital [13][14] - The increase in holdings is based on confidence in the company's long-term value and the need to enhance control [14] - The plan is subject to market conditions and may face risks that could delay or prevent its implementation [15][16]